XPhyto Therapeutics (XPHY.C) announced today that it has successfully launched its 25-minute COVID-19 polymerase chain reaction COVID-ID Lab. “The straightforward testing protocol, without prior RNA extraction as part of…
Xphyto (XPHY.C)
XPhyto Therapeutics (XPHY.C), with its partner and acquisition target, 3a-diagnostics GmbH announced today that it has successfully registered its first biosensor test in oral inflammation with the German authorities….
On July 28, 2021 Xphyto Therapeutics (XPHY.C) announced that its acquisition target, 3a-diagnostics GmbH, has identified the first saliva-activated in-mouth biosensor candidates for the detection of a COVID-19 infection….
XPhyto Therapeutics (XPHY.C) announced today that it has signed a master supply agreement with Beovita GmhB and Tackleberries GmbH, two German diagnostics, testing and medical logistics companies. Cumulatively, both…
XPhyto Therapeutics (XPHY.C) announced today that its Good Manufacturing Practice (GMP) mescaline synthesis program is on schedule with the completion of initial production batches. “With both its North…
XPhyto Therapeutics (XPHY.C), a bioscience accelerator in the life science industry, announced today that its drug formulation programs are advancing on schedule and continue to expand in scope. “Vektor…
XPhyto Therapeutics (XPHY.C) has delivered 2,000 of its rapid, 25-minute polymerase chain reaction (PCR) tests, COVID-ID Lab, to an established medical distributor in Israel for clinical evaluation for the…
The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports….
“PCR tests are used to directly detect the presence of an antigen, rather than the presence of the body’s immune response, or antibodies,” states Medical Device Network, “By detecting…
The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports….